Molecular pathological signatures of gastric cancer in Koreans revealed by label-free proteomics

Hee Jung Sul

Hallym University Sacred Heart Hospital

Jong Bok Seo

korea basic research institute seoul center

Sung-Hwa Sohn

Hallym University Sacred Heart Hospital

Ji Woong Cho

Hallym University Sacred Heart Hospital

Kab Choong Kim

Hallym University Sacred Heart Hospital

A-Young Kim

Ilson Institute of Life Science

Boram Han

Hallym University Sacred Heart Hospital

Hyeong Su Kim

Hallym University Sacred Heart Hospital

Hyun Lim

Hallym University Sacred Heart Hospital

Ho Suk Kang

Hallym University Sacred Heart Hospital

Jae Seung Soh

Hallym University Sacred Heart Hospital

Jinwon Seo

Hallym University Sacred Heart Hospital

Young Ho Koh

Ilson Institute of Life Science

Dae Young Zang (✉ fhdzang@gmail.com)

hallym University Medical Center, Hallym University College of Medicine

Research article

Keywords: Stomach neoplasm, Label-free proteomics, fusion proteins, TPM4-ALK, ARG2, ARG3

Posted Date: September 12th, 2019

DOI: <https://doi.org/10.21203/rs.2.14315/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background Recent studies in gastric cancer (GC) suggested that it could be a heterogeneous disease caused by various genetic defects in combination with environmental risk factors. In this study, a quantitative label-free proteomic analysis were performed to detect differentially expressed proteins and fusion proteins that are only expressed in GC tissues and to identify the signal transduction pathways involved in the tumorigenesis of GC in Korean patients. **Methods** We identified 72 up- and 29 down-regulated proteins in at least 5 out of 9 GC tissues compared with paired normal tissues. **Results** These proteins were divided into 6 highly interacting clusters and 5 relatively related groups for which no interactions have been reported to date but cellular and molecular functions may be shared. Interestingly, the clusters and groups harbored targets for cancer drugs and prognostic markers for several cancers. In addition to these similarities to other cancers, the expression levels of Actinin α -4 (ACTN4), Arginase 2 (ARG2) and ARG3 were significantly decreased in GC, suggesting differences in signaling in Korean GC compared with other cancers. Furthermore, we identified 2 fusion proteins that were expressed only in GC tissues and not in normal gastric tissues: Tropomyosin 4 (TPM4)-Anaplastic lymphoma receptor tyrosine kinase (ALK) and heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1)-Family with sequence similarity 96 member A (FAM96A). **Conclusions** Our label-free proteomic and biochemical analysis revealed that Korean GC showed tumorigenesis signaling characteristics shared with other cancers in addition to presenting novel defects, such as fusion proteins and altered expression of ACTN4, ARG2 and ARG3.

Background

Gastric cancer (GC) is the third most prevalent cause of cancer-related death in the world [1]. In addition, GC was the second most common cancer in Korea in 2013, followed by thyroid cancer. The incidence rate of GC was 13.4% among total reported cancer cases. The mortality caused by GC in Korea was 11.6% in 2014, followed by lung cancer and liver cancer (<http://www.cancer.go.kr/mbs/cancer/index.jsp>). Recent changes in dietary habits and lifestyles in Korea may contribute to the progressive reduction of age-standardized GC mortality rates (<http://www.cancer.go.kr/mbs/cancer/index.jsp>). However, the increase in the elderly population (above 65 years of age) and the discovery of early GC according to the popularization of endoscopic examination have resulted in increased overall incidence rates. This trend is a common phenomenon worldwide according to reports from GLOBOCAN 2012 (<http://globocan.iarc.fr/Default.aspx>) [2].

The genetic basis of GC has recently been extensively investigated, revealing that GC may not be a homogenous disease but rather a complex of diseases caused by a combination of numerous genetic mutations and environmental risk factors [3, 4]. Several genomic studies in GC have suggested that mutations identified in GC tissues are diverse according to the type of GC, age of onset, race, and carcinogenic stomach regions. Numerous mutations, including both germline and somatic mutations, are differentially present in individual GC tissues. In contrast to genomic studies, proteomic studies on

GC have not been intensively conducted to date, despite the fact that signal transduction pathways are mostly regulated by proteins expressed in cells and tissues.

One of the major goals in cancer proteomic research is to identify prognostic or predictive biomarkers for cancer patients by identifying differentially expressed proteins in cancer tissues [5]. Compared with other cancers, prognostic or predictive biomarkers for GC have not been extensively defined to date. One clinically applicable prognostic marker for GC is human epidermal growth factor receptor 2 (HER2), which was initially identified in breast cancer and is observed in ~ 20% of recurrent or metastatic cancer patients [6].

Among cancer-causative mutations, fusion genes resulting from chromosomal translocations and rearrangements are well known driver mutations for numerous types of cancers [7]. The first and best-investigated fusion gene was identified in chronic myelogenous leukemia (CML) and arose through fusion of the breakpoint cluster region (BCR) gene and the Abelson murine leukemia viral oncogene homolog 1 (ABL1) gene [8]. The identification of BCR-ABL1 fusion genes in CML led to the development of the targeted cancer drug imatinib, a tyrosine kinase inhibitor [9]. Fusion genes have also been found in solid tumors. For example, fusion of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma receptor tyrosine kinase (ALK) gene was reported to occur 4% of non-small cell lung cancer patients [10]. EML4-ALK-positive patients showed significant clinical benefits when they were prescribed the ALK inhibitor crizotinib (PF02341066).

Recent studies addressing the therapeutic effect of cancer treatments have suggested that genetic differences among cancer patients might be the most important factor determining the efficacy of treatments [11]. Thus, a recent trend in the treatment of cancer patients is the prescription of targeted drugs specific for certain mutations, after identifying genetic defects in cancer patients. One example of a targeted GC drug is Herceptin, a monoclonal antibody that specifically binds and inhibits the activity of HER2. Herceptin could have great clinical beneficial effect in ~20% of advanced HER2-positive GC patients when combined with chemotherapy [6, 12]. Additional targets for developing targeted GC therapies include vascular endothelial growth factor receptor 2, Human Epidermal Growth Factor Receptor 3, Phosphatidylinositol 4, 5-bisphosphate 3-kinase catalytic subunit- α , MET and the fibroblast growth factor receptors [13].

For completely personalized medicine, additional genetic defects present in GCs must be elucidated. In this study, we employed quantitative and qualitative label-free proteomics to identify differentially expressed proteins (DEPs) and fusion proteins that are exclusively present in GC tissues and not in normal tissues. The identified DEPs and fusion genes could be used as prognostic and predictive markers and targets for developing tools for precision medicines.

Methods

Clinical tissue samples

A total of nine pairs of gastric cancer and adjacent normal tissues were collected from informed and consented GC patients who underwent gastric resection at Hallym University Sacred Hospital in 2011. Details regarding patient clinical data are summarized in Additional file 1. Core areas of the tumors, avoiding necrotic tissues and adjacent normal tissues, as confirmed by a pathologist, were used in this study. This research was approved by the clinical trial committee of Hallym University Sacred Hospital (Approval No.: 2011-I057). In addition, all experiments in this study performed an accordance with the relevant guidelines and regulations. Experimental protocols used in this study were approved by a named institutional/licensing committee.

Protein extraction

For the label-free proteomic analysis, proteins were extracted from gastric cancer and adjacent normal control tissues with the T-PER Tissue protein extraction kit (Pierce Biotechnology, Rockford, IL). Briefly, 20 to 30 mg of tissue was ground with glass beads in 200 μ L of the T-PER reagent containing protease inhibitors (Roche Diagnostics, Basel, Switzerland), followed by sonication using 6 bursts of 30 s. The protein extracts were subsequently centrifuged for 10 min at 15,000 g to obtain soluble fractions. All steps were performed on ice. Total proteins in the soluble fractions were quantified using the BCA assay. The supernatant was mixed with the loading buffer (Tris 40 mM pH 7.5, 2% SDS, 10% glycerol, 25 mM DTT), and the mixture was boiled for 5 min at 95°C. Then, 30 μ g of protein per lane was loaded into a 12% SDS-PAGE gel. The gels were subsequently cut to separate each sample lane, and each lane was divided into 5 pieces. Finally, each piece was digested with trypsin gold, and the peptides were extracted and completely dried.

Label-free quantitative proteomics

Tryptic peptides were analyzed in triplicate using a nanoAcquity UPLC (Waters, Milford, MA) coupled to a Synapt G1 HDMS mass spectrometer (Waters). Peptides were separated using a BEH 130 C18 75 μ m x 250 mm column with a particle size of 1.7 μ m (Waters) and enriched on a Symmetry C18 RP (180 μ m x 20 mm, particle size 5 μ m). For each experiment, 2 μ L of tryptic-digested peptides was loaded onto the enrichment column with mobile phase A (water with 0.1% formic acid). A step gradient was employed at a flow rate of 280 nL/min, which included 5 to 45% mobile phase B (0.1% formic acid with acetonitrile) over 55 min, followed by a sharp increase to 90% B within 10 min. The eluted peptides were analyzed in positive ionization mode using the data-independent MS^E mode. The MS/MS peaks of [Glu1]-fibrinopeptide (400 fmol/ μ L) were employed to calibrate the time-of-flight analyzer in the range of m/z 50 to 1990, and a doubly charged [Glu1]-fibrinopeptide ion (m/z 785.8426) was employed for lock mass correction. During data acquisition, the capillary voltage was set at 3.2 kV, and the source temperature was set at 100°C. The collision energies for low-energy MS mode (intact peptide ions) and elevated-

energy mode were set to the 6 eV and 15 to 40 eV energy ramping modes (peptide product ions), respectively. The scan time was set to 1.0 s.

LC-MS^E raw data files were processed, and protein identification and relative quantitative analyses were all performed using the ProteinLynx Global Server (PLGS 2.5.1, Waters). The processing parameters included automatic tolerance for precursor and product ions, a minimum of 3 fragment ion matches per peptide, a minimum of 7 fragment ion matches per protein, a minimum of 2 peptide matches per protein with a maximum false positive rate (FPR) of 4%, carbamidomethylation of cysteine (+57 Da) as a fixed modification and oxidation of methionine (+16 Da) as a variable modification, and one allowed missed cleavage. Proteins were identified by the ion accounting algorithm of PLGS software, searching the *Homo sapiens* (Human) database (70,718 entries) on the UniProt website (<http://www.uniprot.org>).

The quantitative analysis was based on measuring the peptide ion peak intensities observed in low-collision-energy mode in a triplicate set and was performed using Waters expression, which is part of PLGS 2.5.1. Datasets were normalized using the auto-normalization function. All proteins were identified with a confidence of >95%, and identical peptides from each triplicate set for each sample were clustered based on mass precision and a retention time tolerance of <0.25 min using clustering software included in PLGS 2.5.1. Only those proteins identified in at least two of three technical instrument replicates with a greater than 80 protein probability score were selected for qualitative and quantitative analysis.

To identify fusion proteins in GCs, we used a fusion protein database from the Catalogue of Somatic Mutations in Cancer (COSMICv77: <http://cancer.sanger.ac.uk/cosmic>). Regions of the amino acid sequences of fusion proteins that match peptides are highlighted in color, according to the key below.

Matched a peptide:
Matched a partial peptide:
Matched a modified peptide:
Matched a partial modified peptide:

Twenty-six candidate fusion proteins were manually confirmed to determine whether a peptide spanning the junctional region of two proteins was detected (Additional file 3).

Prediction of three-dimensional structures of fusion proteins

Three-dimensional (3-D) homology models of two fusion proteins were generated at MArkovian TRAnSition of Structure evolution: Protein 3-D Structure Comparison (<http://strcomp.protein.osaka-u.ac.jp/matras/>). Visualization and modification of 3-D fusion protein models were accomplished with Swiss PDB viewer 4.0.1 (Swiss Institute of Bioinformatics).

Western blot analysis

Protein extracts from normal and cancer tissues were separated via 12% SDS-PAGE and then transferred to nitrocellulose membranes. After blocking with 5% non-fat dried milk in TBST, mouse anti-TPM3 and anti-TPM4 (Developmental Study Hybridism Bank, University of Iowa, Ames, IO) antibodies were used to detect proteins from 5 pairs of GC samples and normal controls. Monoclonal anti-b-actin antibodies (Sigma-Aldrich, St. Louis, MO) were used as a loading control.

Data availability

The raw data acquired during this study will be provided upon request.

Results

Differentially expressed proteins in Korean GC patients

To identify DEPs in GC tissues, we performed label-free proteomics using 9 pairs of cancer and matched normal stomach tissues. We found that 72 and 29 proteins were commonly up- or down-regulated, respectively, in at least 5 GC tissues compared with normal control tissues (Fig. 1, Additional file 2)

To investigate the Gene Ontology categories of the DEPs, up- or down-regulated proteins were loaded into the Panther database (www.pantherdb.org) for categorization according to biological processes. Among the 72 up-regulated proteins identified in GCs, 42, 34, 23, and 21 proteins were allocated to the metabolic process, cellular process, localization, and cellular component organization or biogenesis categories, respectively. In contrast, among the 29 down-regulated proteins, 13, 11, 10, and 9 proteins were allocated to the multicellular organismal process, metabolic process, developmental process, and cellular process categories, respectively (Fig. 1).

To further investigate the molecular and cellular etiology underlying the pathogenesis of Korean GC, the interactions between DEPs in Korean GC tissues were investigated using the Search Tool for Recurring Instances of Neighboring Genes (STRING) database (www.STRING-db.org). Fig. 2 presents the results of STRING analysis. Red nodes indicate up-regulated proteins, and blue represents down-regulated proteins in cancer tissues. The colored lines between nodes represent the various types of interaction evidence [14]. The DEPs were further divided into 6 clusters that contained most of the highly interacting DEPs and

5 groups that did not interact within groups but had similar known or predicted functions (Additional file 2).

Altered expression of proteins regulating the actin cytoskeleton and motor activity

Cluster I contained components of two major pathways: regulation of the actin cytoskeleton and motor activities. Interestingly, Actin-binding proteins and cross-linkers, such as Actinin a-4 (ACTN4), Actinin a-1, Actinin a-1 skeletal muscle, Moesin (MSN), Vinculin, and Transgelin, were consistently down-regulated in GCs. The expression levels of ACTN4 in pancreatic, ovarian, lung, and salivary gland cancer [15] and MSN in breast cancer [16] were altered. In contrast, the levels of proteins regulating actin polymerization, such as Actin-related protein 3 Homolog, IQ motif-containing GTPase activating protein 1 (IQGAP1), Adenylate cyclase-associated protein 1, GDP dissociation inhibitor 2, and Rho GTPase activating protein 1, were significantly increased in GCs. Among these proteins, up-regulation of IQGAP1 is known to be involved in tumorigenesis in lung, ovarian, stomach, and colon cancers [17].

Motor activity regulatory components, such as Myosin light chain 9, regulatory (MYL9), Myosin light chain 6, alkali, smooth muscle and non-muscle, Tropomyosin 1-a (TPM1), Tropomyosin 2-b, and Tropomyosin 3 (TPM3), were down-regulated in GCs. However, Myosin Heavy Chain 9, non-muscle (MYH9) was up-regulated. Among these proteins, MYL9 [18], TPM1 [19] and MYH9 [20] are known to be involved in tumorigenesis in various cancers. Other down-regulated components included intermediate filament components such as Vimentin and Desmin (Fig. 2I), which are highly associated with hepatocellular carcinoma [21] and colorectal cancer [22], respectively.

Significantly up-regulated major components of microtubules

Among the diverse Tubulins present in humans, 6 α -Tubulins [Tubulin α (TUBA)-1A, TUBA-1B, TUBA-1C, TUBA-3E, TUBA-4A, and TUBA-8], 7 β -Tubulins [Tubulin β (TUBB), TUBB-2A, TUBB-2B, TUBB-3, TUBB-4A, TUBB-4B, TUBB-6, and TUBB-8], and two regulatory components [Filamin A (FLNA), Chaperonin containing TCP1 subunit 6A] were significantly up-regulated in GCs (Fig. 2 II). β -Tubulins are established targets for anti-cancer drugs [23], and FLNA was reported to be up-regulated in breast cancer tissues [24].

Altered ion-binding proteins in GCs

Among the DEPs, iron- and oxygen-binding proteins, such as Hemoglobin (HB) subunit-b, HB subunit-g2, HB subunit-d, HB subunit-e1, and HB subunit-g1 were significantly down-regulated in GCs. In addition, the binding of Albumin to Ca^{2+} , Na^{+} , and K^{+} was down-regulated in GCs. In contrast, another iron-binding

protein, Transferrin, and the zinc-containing Carbonic anhydrase enzymes were significantly up-regulated in GCs (Fig. 2 III).

Up-regulated glycolysis metabolism-associated proteins in GCs

Proteins in Cluster IV are involved in various metabolic processes. Among these proteins, Glyceraldehyde-3-phosphate dehydrogenase, Enolase 1 (ENO1), ENO2, Glucose-6-phosphate isomerase (GPI), Pyruvate kinase muscle (PKM), and Phosphoglycerate Kinase 1 (PGK1) are highly associated with glycolysis.

These genes were up-regulated and closely associated each other. This cluster also included the down-regulated Malate Dehydrogenase 1, ATP synthase H⁺ transporting mitochondrial F1 complex a-subunit and cardiac muscle and the up-regulated Citrate Synthase found in mitochondria (Fig. 2 IV).

Most molecular chaperone-related proteins were up-regulated

Cluster V (Fig. 2V) included two hub molecular chaperones, Heat Shock Protein (HSP) 90 kDa cytosolic-a class A member 1 and HSP90 a-family class b member 1, which strongly interacted with HSP family A member 1 like, HSP family A member 2, HSP family A member 5, HSP family A member 6, HSP family A member 8, HSP family A member 9, HSP family D member 1, Hypoxia up-regulated 1, and HSP B member 1 (HSPB1). With the exception of HSPB1, all HSPs were up-regulated in GCs.

Up-regulated proteins with protein folding and trafficking activities

Cluster VI (Fig. 2VI) included up-regulated proteins that localized to the Golgi apparatus (GA) or endoplasmic reticulum (ER) and regulated protein folding and trafficking. Valosin-containing protein, Major histocompatibility complex class 1 (HLA)-B, HLA-C, Ribophorin II (RPN2), Protein disulfide isomerase family A (PDIA) member-3, PDIA member-6, Prolyl 4-hydroxylase subunit-b, Calnexin (CANX), Calreticulin (CALR), Thioredoxin domain containing 5, and Glucosidase II a-subunit were significantly up-regulated proteins.

Up-regulated proteins involved in protein synthesis

Three proteins involved in protein synthesis: Eukaryotic translation elongation factor (EEF)-2, EEF-1A1, and EEF-1A2, were up-regulated and interacted with components in other clusters. Among these proteins, EEF1A2 is involved in tumorigenesis in ovarian cancer [25].

Down-regulated proto-oncogenes and up-regulated peptidase inhibitors in GCs

Proto-oncogenes, such as Anterior gradient 2 [26, 27], Anterior gradient 3 [27], Ras suppressor-1 [28], SET nuclear proto-oncogene [29], Tryptophanyl-tRNA synthetase [30], and Ubiquitin-like modifier activating enzyme 1 [31], were significantly down-regulated in GCs (Fig. 2B). In addition, Serpin peptidase inhibitor clade (SERPIN)-A member 1 (SERPINA1), which is involved in tumor progression in GCs [32] and colorectal cancer [33], and SERPIN-H member 1, which has been identified as a potential biomarker for early-stage hepatocellular carcinoma [34], were found to be significantly increased in GCs in the present study.

Altered proteins involved in energy metabolism and cellular structural components

Creatine kinase B, which regulates energy homeostasis in tissues and is decreased in cervical cancers [35], was down-regulated in GCs. In contrast, ATPase Na⁺/K⁺-transporting subunit a-1, which maintains energy homeostasis; mitochondrial Aldehyde dehydrogenase 2 family, which oxidizes aldehydes to generate carboxylic acids; and Gastric type Lipase F, an enzyme involved in the digestion of dietary triglycerides, were significantly up-regulated in GCs.

Other proteins with multiple domains that are important for organizing cellular structures also exhibited alterations. For example, POTE Ankyrin domain family member (POTE)-J and POTEI were down- and up-regulated in GCs, respectively. Lumican, a member of the small leucine-rich proteoglycan family that regulates collagen fibril organization and is involved in prostate cancers [36], was significantly down-regulated in GCs. Major vault protein is highly overexpressed in drug-resistant cancers [37]. Karyopherin subunit b-1, Junction Plakoglobin, Lamin A/C, Multiple PDZ domain crumbs cell polarity complex component, Clathrin heavy chain, and Leucine-rich pentatricopeptide repeat-containing were up-regulated.

Label-free proteomic analysis identified 2 fusion proteins in GC

We searched MS data obtained from 9 pairs of GC and normal tissues using the COSMIC fusion gene database. Twenty-six candidate fusion proteins were obtained (Additional file 2). We manually examined whether peptides spanning the junction of two proteins were identified by mass spectrometry. Only 2 fusion proteins were confirmed to have a corresponding peptide spanning two proteins: TPM4-ALK and hnRNPA2B1-FAM96A (Additional file 2).

To gain further insight into the possible roles of the 2 fusion proteins in tumorigenesis, the 3-D structures of the two fusion proteins were predicted by performing homology modeling. The 3-D structure of the TPM4-ALK fusion protein showed that it contains an ALK kinase domain and a TPM that primarily consists of an alpha helix and may assemble into parallel dimeric coiled-coils with normal TPM4 or other TPM4-ALK fusion proteins (Fig. 3a). The 3-D modeling of the hnRNPA2B1-FAM96A fusion protein revealed that the fusion protein presented as a dimer, given that FAM96A is known to form dimers [38]. The ability of the fusion proteins to dimerize suggested that the localization of the fusion proteins could be different from that of the normal proteins and might alter cellular and molecular processes.

Increased size of bands recognized by monoclonal TPM4 antibodies in GC tissues

To confirm the presence of TPM4-ALK fusion proteins, we performed Western blot analysis using monoclonal antibodies specific to TPM3 or TPM4. Anti-TPM4 antibodies recognized bands of increased sizes that were not detected in normal gastric tissues. However, anti-TPM3 antibodies did not detect any additional bands. Only one band from GC tissues showed the same migration pattern observed in normal gastric tissues (Fig. 4).

Discussion

The development of new therapeutic methods for GC has contributed to remarkably decreased mortality worldwide [13]. Nevertheless, GCs remain one of the most common cancers in Korea and Asia [2]. Given that GC is associated with heterogeneous genetic defects [1, 3], we must elucidate specific genetic defects at the protein level in each patient to expand the efficacy of personalized medicine [39]. In this study, we employed label-free proteomic analysis to investigate DEPs and fusion proteins in Korean GC tissues. The DEPs identified in this study could be divided into 6 highly associated clusters and 5 relatively linked groups. These 5 groups were manually curated based on their reported or predicted functions because direct interactions between them have not yet been determined (Fig. 2).

Interestingly, the 6 clusters identified in this study harbored targets for currently prescribed cancer drugs or their homologs as well as proteins known to play pivotal roles in tumorigenesis and metastasis. For example, various β -Tubulins are known targets for Paclitaxel and Vinca alkaloids that inhibit chromosome mitosis and angiogenesis in tumor cells [23], and these targets formed a cluster (Fig. 2II). In addition, the levels of heat shock molecular chaperones, which are increased in most cancers [40], were found to be significantly increased in the present work as well and formed a cluster (Fig. 2V).

Furthermore, ER- and GA-resident components, which regulate protein folding, modifications, and trafficking, were also significantly increased and formed a cluster. Among these proteins, RPN2, a component of an N-oligosaccharyl transferase complex that is involved in anti-cancer drug resistance in breast cancer [41] and non-small cell lung cancer [42], was significantly increased, suggesting possible conservation of drug resistance and metastasis mechanisms in GC. In addition, the significant increases in HSPA5, CALR and CANX in GC (Fig. 2V and 2VI) suggested that the unfolded protein response (UPR) might be activated in GC, similar to the activation of the UPR observed in *Helicobacter*-induced GC [43], to overcome hypoxia and a low nutrient supply, which are two initial stress conditions observed in cancer cells that induce aggressiveness in a murine model of melanoma [44]. Interestingly, we also identified a cluster harboring significantly up-regulated glycolytic enzymes, such as PKM, PGK1, ENO1, ENO2, and GPI (Fig. 2 IV). Recent studies on cancer metabolism have suggested that up-regulation of glycolytic enzymes is associated with tumorigenesis and drug resistance [45, 46] and could be used as prognostic bio-markers [47]. Considering these findings together, most of the DEPs identified in this study are already known to be linked to tumorigenesis, metastasis, and drug resistance.

Another interesting finding of this study was the two fusion proteins identified in GCs (Fig. 3 and Additional file 3). The use of targeted cancer drugs has several advantages, such as high responsive rates with lower side effects in treatments [39]. However, only one targeted GC drug, Herceptin, is currently used to treat GC, and Herceptin is only effective in ~ 20% of HER2-positive GC patients [6, 12]. Thus, to realize precision medicine in GC, new target genes or proteins should be elucidated. The two fusion proteins identified in this study are very intriguing given that ALK fusion genes are driver mutations in several cancers and targets for developing targeted cancer drugs [48]. In addition, hnRNPA2B1 also regulates the expression of tumor suppressor genes [49] and down-regulation of FAM96A has been reported in gastrointestinal stromal tumors (GISTs) [50]. Furthermore, 3-homology modeling of fusion proteins suggested that they could form hetero- or homodimers with normal proteins or fusion proteins. Upon dimerization, the fusion proteins were found at sites where normal proteins were not located, resulting in abnormal activities of ALK, hnRNPA2B1, or FAM96A. These abnormal activities of the two fusion proteins could transform normal cells to cancer cells.

Conclusions

In this study, we identified DEPs and fusion proteins expressed in Korean GC. The identified DEPs and fusion proteins could be used as prognostic and predictive biomarkers for GC. In addition, future studies involving DEPs and fusion gene models will provide us with new tools to cure advanced or metastatic GCs. These efforts will help to expand the potential of personalized medicine in the near future.

Abbreviations

GC: gastric cancer; ACTN4: Actinin a-4; ARG2: Arginase 2; TPM4: Tropomyosin 4; ALK: Anaplastic lymphoma receptor tyrosine kinase; hnRNPA2B1: heterogeneous nuclear ribonucleoprotein A2/B1; FAM96A: Family with sequence similarity 96 member A; HER2: human epidermal growth factor receptor 2; CML: chronic myelogenous leukemia; BCR: breakpoint cluster region; ABL1: Abelson murine leukemia viral oncogene homolog 1; EML4: echinoderm microtubule-associated protein-like 4; ALK: anaplastic lymphoma receptor tyrosine kinase; DEPs: differentially expressed proteins; STRING: Search Tool for Recurring Instances of Neighboring Genes; ACTN4: Actinin a-4; MSN: Moesin; IQGAP1: IQ motif-containing GTPase activating protein 1; MYL9: Myosin light chain 9, regulatory; TPM: Tropomyosin; MYH9: Myosin Heavy Chain 9, non-muscle; TUB: Tubulin; FLNA: Filamin A; HB: Hemoglobin; ENO1: Enolase 1; GPI: Glucose-6-phosphate isomerase; PKM: Pyruvate kinase muscle; PGK1: Phosphoglycerate Kinase 1; HSP: Heat Shock Protein; GA: Golgi apparatus; ER: endoplasmic reticulum; HLA: Major histocompatibility complex class 1; RPN2: Ribophorin II; PDIA: Protein disulfide isomerase family A; CANX: Calnexin; CALR: Calreticulin; EEF: Eukaryotic translation elongation factor; SPERPINA1: Serpin peptidase inhibitor clade (SERPIN)-A member 1; UPR: unfolded protein response; GISTs: gastrointestinal stromal tumors.

Declarations

Ethical approval and consent to participate

Ethical registry was obtained from the Institutional Review Board and Ethics Committee of Hallym University Sacred Heart Hospital prior to the beginning of the study under No:2011-I057. Written, informed consent was obtained from all participants prior to their inclusion in this study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed for the current study are available from the corresponding author on reasonable request.

Competing interests

All authors declared no competing interests.

Funding

This work was supported by the Ministry of Food and Drug Safety (awarded in 2018, 18183MFDS491) of Korea, the National R&D Program for Cancer Control, Ministry of Health and Welfare (HA17C0054), and the Hallym University Research Fund.

Author Contributions

YHK and JBS analyzed data and drafted the article. HJS, SHS, and AYK performed molecular experiments. HSK, BRH, JWC, KCK, HL, HSK, JSS, and JS material support and analyzed the clinicopathological results, YHK and JBS critical revision of the manuscript for important intellectual content. DYZ study supervision, obtained funding, guided the analysis of data and edited the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. McLen MH, El-Omar EM: **Genetics of gastric cancer.** *Nat Rev Gastroenterol Hepatol* 2014, **11**:664-674.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: **GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide.** In: *IARC CancerBase No 11 [Internet]*. vol. 1.0: International Agency for Research on Cancer; 2015.
3. TCGA: **Comprehensive molecular characterization of gastric adenocarcinoma.** *Nature* 2014, **513**:202-209.
4. Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K *et al*: **Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.** *Nat Med* 2015, **21**:449-456.
5. Tainsky MA: **Genomic and proteomic biomarkers for cancer: A multitude of opportunities.** *BBA-Reveiwrs on Cancer* 2009, **1796**:176-193.
6. Gravalos C, Jimeno A: **HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.** *Ann Oncol* 2008, **19**:1523-1529.
7. Mertens F, Johansson B, Fioretos T, Mitelman F: **The emerging complexity of gene fusions in cancer.** *Nat Rev Cancer* 2015, **15**:371-381.
8. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV: **The Presence of Typical and Atypical BCR-ABL Fusion Genes in Leukocytes of Normal Individuals: Biologic Significance and Implications for the Assessment of Minimal Residual Disease.** *Blood* 1998, **92**:3362-3367.
9. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S *et al*: **Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia.** *N Engl J Med* 2001, **344**:1031-1037.
10. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, De Pas T, Besse B, Solomon BJ, Blackhall F *et al*: **Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer.** *N Engl J Med* 2013, **368**:2385-2394.
11. Editorial: **Genome variation in precision medicine.** *Nat Genet* 2016, **48**:701-701.
12. Bang YJ, Cutsem E, V, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T *et al*: **Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.** *Lancet* 2010, **376**:687-697.
13. Wong H, Yau T: **Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?** *Therap Adv Gastroenterol* 2013, **6**:15-31.
14. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP *et al*: **STRING v10: protein-protein interaction networks, integrated over the tree of life.** *Nucleic Acids Res* 2015, **43**:D447-D452.
15. Honda K: **The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer.** *Cell Biosci* 2015, **5**:1-9.

16. Wang C-C, Liao J-Y, Lu Y-S, Chen J-W, Yao Y-T, Lien H-C: **Differential expression of moesin in breast cancers and its implication in epithelial–mesenchymal transition.** *Histopathology* 2012, **61**:78-87.
17. Johnson M, Sharma M, Henderson BR: **IQGAP1 regulation and roles in cancer.** *Cell Signal* 2009, **21**:1471-1478.
18. Tan X, Chen M: **MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data.** *Tumor Biol* 2014, **35**(12):12189-12200.
19. Zhu S, Si M-L, Wu H, Mo Y-Y: **MicroRNA-21 targets the tumor suppressor gene Tropomyosin 1 (TPM1).** *J Biol Chem* 2007, **282**:14328-14336
20. Schramek D, Sendoel A, Segal JP, Beronja S, Heller E, Oristian D, Reva B, Fuchs E: **Direct in vivo RNAi screen unveils Myosin IIa as a tumor suppressor of squamous cell carcinomas.** *Science* 2014, **343**:309-313.
21. Hu L, Lau SH, Tzang C-H, Wen J-M, Wang W, Xie D, Huang M, Wang Y, Wu M-C, Huang J-F *et al*: **Association of Vimentin overexpression and hepatocellular carcinoma metastasis.** *Oncogene* 2004, **23**:298-302.
22. Arentz G, Chataway T, Price TJ, Izwan Z, Hardi G, Cummins AG, Hardingham JE: **Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels.** *Clin Proteomics* 2011, **8**:1-13.
23. Jordan MA, Wilson L: **Microtubules as a target for anticancer drugs.** *Nat Rev Cancer* 2004, **4**:253-265.
24. Tian H, Liu X, Han W, Zhao L, Yuan B, Yuan C: **Differential expression of filamin A and its clinical significance in breast cancer.** *Oncol Lett* 2013, **6**:681-686.
25. Lee JM: **The role of protein elongation factor eEF1A2 in ovarian cancer.** *Reprod Biol Endocrinol* 2003, **1**:1-5.
26. Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals JP: **Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma.** *Int J Cancer* 2013, **132**:E85-E93.
27. Chevet E, Fessart D, Delom F, Mulot A, Vojtesek B, Hrstka R, Murray, Gray T, Hupp T: **Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development.** *Oncogene* 2013, **32**:2499-2509.
28. Giotopoulou N, Valiakou V, Papanikolaou V, Dubos S, Athanassiou E, Tsezou A, Zacharia LC, Gkretsi V: **Ras suppressor-1 promotes apoptosis in breast cancer cells by inhibiting PINCH-1 and activating p53-upregulated-modulator of apoptosis (PUMA); verification from metastatic breast cancer human samples.** *Clin Exp Metastasis* 2015, **32**:255-265.
29. Pippa R, Dominguez A, Malumbres R, Endo A, Arriazu E, Marcotegui N, Guruceaga E, Odero MD: **MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.** *Oncotarget* 2017, **8**:53989-54003.
30. Ghanipour A, Jirström K, Pontén F, Glimelius B, Pahlman L, Birgisson H: **The prognostic significance of Tryptophanyl-tRNA synthetase in colorectal Cancer.** *Cancer Epidemiol Biomarkers Prev* 2009, **18**:2949-2956.

31. Xu W, Lukkarila JL, Silva SRd, Paiva S-L, Gunning PT, Schimmer AD: **Targeting the Ubiquitin E1 as a Novel Anti-Cancer Strategy.** *Curr Pharm Des* 2013, **19**:3201-3209.
32. Kwon CH, Park HJ, Lee JR, Kim HK, Jeon TY, H-J. J, Kim DH, Kim GH, Park DY: **Serpin peptidase inhibitor clade A member 1 is a biomarker of poor prognosis in gastric cancer.** *Br J Cancer* 2014, **111**:1993-2002.
33. Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo H-j, Kim HS, Oh N, Song GA, Park DY: **Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer.** *Br J Cancer* 2014, **6**:20312-20326.
34. Naboulsi W, Megger DA, Bracht T, Kohl M, Turewicz M, Eisenacher M, Voss DM, Schlaak JF, Hoffmann A-C, Weber F *et al*: **Quantitative Tissue Proteomics Analysis Reveals Versican as Potential Biomarker for Early-Stage Hepatocellular Carcinoma.** *J Proteome Res* 2016, **15**:38-47.
35. Choi H, Park CS, Kim BG, Cho JW, Park J-B, Bae YS, Bae DS: **Creatine Kinase B Is a Target Molecule of Reactive Oxygen Species in Cervical Cancer.** *Mol Cells* 2001, **12**:412-417.
36. Coulson-Thomas VJ, Coulson-Thomas YM, Gesteira TF, Andrade de Paula CA, Carneiro CR, Ortiz V, Toma L, Kao WW, Nader HB: **Lumican expression, localization and antitumor activity in prostate cancer.** *Exp Cell Res* 2013, **319**:967-981.
37. Ryu SJ, An HJ, Oh YS, Choi HR, Ha MK, Park SC: **On the role of major vault protein in the resistance of senescent human diploid fibroblasts to apoptosis.** *Cell Death Differ* 2008, **15**:1673-1680.
38. Chen K-E, Richards AA, Ariffin JK, Ross IL, Sweet MJ, Kellie S, Kobe B, Martin JL: **The mammalian DUF59 protein Fam96a forms two distinct types of domain-swapped dimer.** *Acta Crystallographica Section D* 1107, **68**:637-648.
39. Shork NJ: **Personalized medicine: Time for one-person trials.** *Nature* 2015, **520**:609-611.
40. Ciocca DR, Calderwood SK: **Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications.** *Cell Stress Chaperones* 2005, **10**:86-103.
41. Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T: **RPN2 gene confers docetaxel resistance in breast cancer.** *Nat Med* 2008, **14**:939-948.
42. Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K, Ochiya T: **Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.** *Oncotarget* 2015, **6**:3335-3345.
43. Baird M, Ang PW, Clark I, Bishop D, Oshima M, Cook MC, Hemmings C, Takeishi S, Worthley D, Boussioutas A *et al*: **The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner.** *Lab Invest* 2013, **93**:112-122.
44. Osawa T, Muramatsu M, Watanabe M, Shibuya M: **Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma.** *Cancer Sci* 2009, **100**:844-851.
45. Li X, Jiang Y, Meisenhelder J, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, He J, Hunter T *et al*: **Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis.** *Mol Cell* 2016, **61**:705-719.

46. Pavlova NN, Thompson CB: **The emerging hallmarks of cancer metabolism.** *Cell Metab* 2016, **23**:27-47.
47. Sun S, Liang X, Zhang X, Liu T, Shi Q, Song Y, Jiang Y, Wu H, Jiang Y, Lu X *et al*: **Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.** *Br J Cancer* 2015, **112**:1332-1339.
48. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: **The anaplastic lymphoma kinase in the pathogenesis of cancer.** *Nat Rev Cancer* 2008, **8**:11-23.
49. Golan-Gerstl R, Cohen M, Shilo A, Suh S-S, Bakács A, Coppola L, Karni R: **Splicing factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in glioblastoma.** *Cancer Res* 2011, **71**:4464-4472.
50. Schwamb B, Pick R, Fernández SB, Völpl K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J *et al*: **FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors.** *Int J Cancer* 2015, **137**:1318-1329.

Figures

Figure 1

Gene ontology: biological process analysis of up- or down-regulated genes in GC. The up- (a) or down- (a) regulated proteins identified in GCs were associated with various molecular functions and biological

process.

Figure 2

Search Tool for Recurring Instances of Neighboring Genes (STRING) analysis of up- (red) or down- (blue) regulated proteins identified in gastric cancer tissues compared with normal gastric tissues. Interactions between up- or down-regulated genes were grouped according to their key functional characteristics. Six highly associated clusters were identified. Additional 5 groups were clustered based on their reported or predicted biological and molecular functions.

Figure 3

redicted 3-D structures of 2 fusion proteins. a The 3-D homology modeling of TPM4-ALK fusion proteins revealed possible dimerization via Tropomyosin domains in fusion proteins. b The 3-D homology modeling of hnRNA2B1-FAM96A fusion proteins suggested possible dimerization of fusion proteins via FAM96A dimerization.

Figure 4

Monoclonal TPM4 antibodies recognized large fusion proteins in protein extracts from GC tissues, but not those from normal stomach tissues. a When monoclonal anti-TPM4 antibodies were used, two TPM4 bands were detected in GC tissues but not in normal control stomach tissues. The above bands were predicted to be fusion proteins. b Monoclonal- β -actin antibodies were used as loading controls. c Monoclonal TPM3 antibodies only detected single bands in GC tissues. d The amount of protein loaded in each lane was confirmed with monoclonal β -actin antibodies. Monoclonal- β -actin antibodies were used as loading controls.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfile3.Fusiongenes.docx](#)
- [Supplementaryfile2Labelfreeproteomicslawdata.xlsx](#)
- [Supplementaryfile1.patientinformation.docx](#)